The Laboratory for Cancer Nanotechnology and Immunotherapy focuses on the integration of nanotechnology with oncology and immunology to develop impactful therapeutics for hard-to-treat cancers. The overarching objective is to generate fundamental understanding of the processes pertinent to the use of nanotechnology in cancer nanomedicine and immunotherapy.
The multicomponent nanoparticle platform develops new classes of nanoparticles including (1) chain-like nanoparticles, termed nanochains and (2) mesoporous silica nanoparticles with an iron oxide core. Due to enhanced site-specific targeting and radiofrequency-triggered drug release, the multicomponent nanoparticles facilitate effective delivery of drugs into hard-to-reach tumors, which has the potential to unfold the field and allow significant expansion of therapies to the disease where success is currently very limited.
Representative publications: Peiris et al., ACS Nano 6(5) 2012 | Peiris et al., ACS Nano 6(10) 2012 | Peiris et al., J Control Release 2012 | Peiris et al., Cancer Research 2015 | Turan et al., Nanoscale 2019
Effective antitumor immunity depends on the reprogrammming and robust activation of the tumor immune microenvironment. We design immunostimulatory nanoparticles that carefully consider the unique tumor microenvironment to deliver robust immune-potentiating stimuli and effectively bridge the innate and adaptive arms of the immune system.
We study the design of nanoparticles to improve the spatiotemporal targeting of nanomedicines towards hard-to-treat cancers. Our lab develops nanoparticle imaging agents for anatomical, molecular and phenotypical imaging. Using MRI, CT and nuclear imaging, these nanoparticles facilitate prognostication of the outcome of cancer therapies, non-invasive in vivo interrogation and highly accurate and early diagnosis of disease.